For governments, politicians, doctors, the pharmaceutical industry, and the media, FESCA will be the main focal point for all enquiry. As the EU’s only independent, not-for-profit, focused, umbrella patient organisation with deep expertise in Scleroderma, FESCA is in a position to achieve this.
Run with the motivation and energy of those whose lives are affected by the disease, FESCA has the support of EUSTAR and EULAR-PARE and disseminates expert knowledge while facilitating communications for all European Connective Tissue Disease stakeholders.
FESCA is a clearing house for patients and the medical community, serving as a conduit for the dissemination of funds in support of research and outreach from a multiplicity of sources. With complete transparency in support of research and outreach, FESCA operates in pursuit of a world in which everyone with Scleroderma receives appropriate access to a comparable standard of successful care.
What is Scleroderma?
Scleroderma is a chronic disease characterized by excessive deposits of collagen in the skin or other organs. The localized type of the disease, while disabling, tends not to be fatal.
Diffuse scleroderma or systemic sclerosis, the generalized type of the disease, can be fatal as a result of heart, kidney, lung or intestinal damage.